COVID-19 vaccine: After Pfizer and Moderna, Serum Institute of India to seek indemnity protection

Serum Institute of India (SII), the company producing Covishield vaccines, wants legal protection from any claims linked to their vaccines, ANI reported, quoting unnamed sources.

Covishield (local name of Oxford-Astrazeneca vaccine) is currently the most administered vaccine in India.

India is currently running its third phase of COVID-19 vaccination drive with home-made vaccines -- Covishield -- made by SII, Covaxin -- from Bharat Biotech and Russia’s Sputnik V.

ANI had reported, on June 2, that foreign vaccine makers -- Pfizer and Moderna -- were seeking legal protection before entering the Indian market.

India has so far not given indemnity protection to any manufacturer of COVID-19 vaccines.


SEE ALSO:
OnePlus cryptocurrency wallet could be in the works, company survey suggests
Microsoft, Airtel, BYJU’S, IIT-Bombay and more — here is a list of companies looking for interns
Smartphones launching in India in June 2021